Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of

Pulmonary Arterial Hypertension Drug Market, by Drug Class (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Prostacyclin Analogue, Calcium Channel Blockers, Others), by Route of Administration (Oral, Inhaled, Intravenous, Subcutaneous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Pulmonary arterial hypertension is a rare disease caused by many factors, such as congestive heart failure, liver disease, autoimmune diseases, such as lupus, scleroderma, rheumatoid arthritis, etc. The pulmonary artery is a blood vessel that carries blood from the right side of the heart to the lungs. This disease is considered a rare but life-threatening disease and will get worse over time. The arteries that are narrowed and blocked due to high blood pressure are called pulmonary arterial hypertension (PAH) and pulmonary hypertension (PH). Thus, making it difficult for blood to pump through these arteries, subsequently causing the heart muscle to weaken.

Symptoms include shortness of breath, dizziness, and tightness in the chest. The exact cause of PAH is unknown, and although it can be treated, there is no known cure. Over time, the condition will get worse, but medications and oxygen therapy can help reduce symptoms and improve quality of life. PAH usually affects women between the ages of 30 and 60.

Market Dynamics

The increase in causes of pulmonary arterial hypertension (PAH) such as stroke is expected to drive the growth of global pulmonary arterial hypertension drug market over the forecast period. For instance, according to an article Heart Disease and Stroke Statistics 2019 published by the American College of Cardiology Foundation, a report from the American Heart Association, there are about 795,000 residents in the U.S. who have a new or recurrent stroke each year, in which 90.0% of stroke risk is due to modifiable risk factors and 74.0% is due to behavioral risk factors.

Key features of the study:

• This report provides an in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
• Key companies covered as a part of this study include United Therapeutics Corporation, GlaxoSmithKline plc., Novartis AG, AstraZeneca, Bayer AG, Merck KGaA, Pfizer Inc., Gilead Sciences, Inc., Actelion Pharmaceuticals Ltd, Arena Pharmaceuticals, Daiichi Sankyo Company, Limited, Sandoz AG, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd. and Mylan N.V.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market

Detailed Segmentation:

• Global Pulmonary arterial hypertension Drug Market, By Drug Class:
• Endothelin Receptor Antagonists (ERAs)
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Soluble Guanylate Cyclase (sGC) Stimulators
• Prostacyclin Analogue
• Calcium Channel Blockers
• Others
• Global Pulmonary arterial hypertension Drug Market, By Route of Administration:
• Oral
• Inhaled
• Intravenous
• Subcutaneous
• Global Pulmonary arterial hypertension Drug Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Pulmonary arterial hypertension Drug Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• United Therapeutics Corporation.
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• GlaxoSmithKline plc.
• Novartis AG
• AstraZeneca
• Bayer AG
• Merck KGaA
• Pfizer Inc.
• Gilead Sciences, Inc.
• Actelion Pharmaceuticals Ltd
• Arena Pharmaceuticals
• Daiichi Sankyo Company, Limited
• Sandoz AG
• Reddy's Laboratories Ltd.
• Sun Pharmaceutical Industries Ltd.
• Mylan N.V.

“*” marked represents similar segmentation in other categories in the respective section.